Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

isk for serious medical problems such as acute pancreatitis, accelerated atherosclerosis, and blood vessel and nerve damage from diabetes and liver cirrhosis, which can markedly reduce quality of life and life expectancy. Metreleptin works to treat metabolic abnormalities in patients with lipodystrophy.

It is estimated that there are a few thousand patients worldwide with this condition, although robust epidemiological data are not available, as is common with rare diseases. There are no therapies currently indicated specifically for the treatment of metabolic abnormalities associated with lipodystrophy. Presently, patients may receive a combination of dietary modification, anti-diabetic medications and lipid-lowering agents. These traditional treatment approaches do not address the underlying cause of the metabolic abnormalities in lipodystrophy and are often rendered marginally effective due to the severity of the condition.

About Metreleptin for Lipodystrophy

Data from clinical studies conducted by investigators at the NIH and other academic institutions in the U.S., Europe and Japan, have demonstrated that metreleptin can have profound effects on improving insulin sensitivity, high trigylcerides, hyperglycemia and liver fat in patients with lipodystrophy who are not responsive to conventional lipid and glucose-lowering agents, even those undergoing intensive insulin therapy.

Globally, approximately 150 patients with lipodystrophy are being treated with metreleptin under investigator-sponsored trials and expanded access programs.

In 2010, Amylin submitted the non-clinical and clinical sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in patients with rare inherited or acquired forms of lipodystrophy. The Company plans to submit the chemistry, manufacturing and controls (CMC) se
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Mont., Oct. 25 LigoCyte Pharmaceuticals, Inc. ... vaccine products, today announced positive results from a ... particle (VLP) vaccine candidate. Baylor College of Medicine,s ... data from the trial via an oral presentation ...
... Inc. (Nasdaq: ESRX ) announced that it ... 21st Annual Healthcare Conference on Wednesday, November 3, 2010 ... Wednesday, November 10, 2010 at 8:30 a.m. mountain (10:30 ... Tuesday, November 16, 2010 at 9:55 a.m. eastern. These ...
Cached Medicine Technology:Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 2Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 3Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 4Express Scripts to Present at Investor Conferences in November 2
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... Strategies for Aging Baby,Boomers, ALEXANDRIA, Va., Jan. 23 ... Florida, the nation,s leading professional,association for assisted living is ... needs of America,s aging population --,especially the "baby-boomers" who ... population in Florida and their families deserve to,know what ...
... five years without anti-rejection drugs , , WEDNESDAY, Jan. ... recipients to stop taking powerful immunosuppressive drugs are starting ... the development of the transplant field is to completely ... lifesaving benefit of the transplant without the costs of ...
... EVANSTON, Ill. --- In early 2007, Northwestern University chemist ... Wright reported in the Journal of Natural Products that ... sponge was extremely effective at inhibiting cancer cell growth. ... and their potential in medicine, Scheidt knew what he ...
... Jan. 23, 2008 -- A review of epidemiological data ... in school may experience a slight but statistically significant ... that could be Alzheimer,s disease. , Scientists at ... School of Medicine in St. Louis reviewed data on ...
... types used frequently in consumer research to the ... of two fundamental needs: they are either promotion-focused, ... and aspirations, or they are prevention-focused, seeking items ... security. According to the research, people are better ...
... Proven Success in School Foodservice to Retail Markets, MUNDELEIN, ... ) announced today the retail launch of its headline-making,salad dressings., ... of Z Trim Ranch, Z,Trim Honey Dijon and Z Trim ... Foods grocery store chain in the Chicago area., "We ...
Cached Medicine News:Health News:Assisted Living Federation Challenges Presidential Candidates 2Health News:New Therapies Could Change Organ Transplants 2Health News:New Therapies Could Change Organ Transplants 3Health News:Synthesis of natural molecule could lead to better anti-cancer drugs 2Health News:Synthesis of natural molecule could lead to better anti-cancer drugs 3Health News:Synthesis of natural molecule could lead to better anti-cancer drugs 4Health News:Less education may lead to delayed awareness of Alzheimer's onset 2Health News:Your personality type influences how much self-control you have 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 3
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Kit Nebulizer Small Volume Medication Mouthpiece 7FT O ... ,These Sidestream® nebulizers are designed to ... any nebulizer treatment with a fast treatment time. ... 7` (84") tubing and a vent seal adapter ...
Nebulizer Adapter Kit 6"...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: